Pair page
Sermorelin with Testosterone
Mechanism-tag overlap and published literature for Sermorelin and Testosterone, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrh-analog-growth-hormone-secretagogue
androgenprimary-male-sex-hormone
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Sermorelin and Testosterone have published these mechanism-level observations. Not a co-administration recommendation.
Men on TRT commonly add sermorelin or sermorelin + ipamorelin for a fuller anabolic axis — testosterone for androgen restoration, GH-axis support for body composition and recovery. Requires clinician oversight and monitoring of all three axes.
GH-axis peptides commonly layered onto TRT for full anabolic-endocrine restoration. Mechanistically independent (GH-axis vs androgen axis); additive body-composition benefits.
Quick facts
Sermorelin
Testosterone
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2012 | Sermorelin | Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429.… PMID 22869065 | human study |
| 1999 | Sermorelin | Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID: 18031173. PMID 18031173 | human study |
| 1996 | Sermorelin | Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol. 1996;134(3):352-356. PMID: 8616536. PMID 8616536 | human study |
| 2020 | Sermorelin | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. | mechanism / discovery |
| 2025 | Sermorelin | WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2006 | Sermorelin | Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PMID: 18046908. PMC2699646. PMID 18046908 | research article |
| 2003 | Sermorelin | Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14662999. PMID 14662999 | research article |
| 1997 | Sermorelin | Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in older men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141535. PMID 9141535 | research article |
| 1996 | Sermorelin | Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-1196. PM… PMID 8772599 | research article |
| 1992 | Sermorelin | Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. PMID: 1379256. PMID 1379256 | research article |
| 1992 | Sermorelin | Duck SC, Schwarz HP, Costin G, et al. Subcutaneous growth hormone-releasing hormone therapy in growth hormone-deficient children: first year of therapy. J Clin Endocrinol Metab. 1992;75(4):1115-1120. PMID: 1400880. PMID 1400880 | research article |
| 1985 | Sermorelin | Vance ML, Kaiser DL, Evans WS, et al. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor. Evidence for intermittent somatostatin secretion. J Clin Invest. 1985;75(5):1584-1590. PMID: 2860118. PMID 2860118 | research article |
| 2007 | Testosterone | Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis. Mayo Clin Proc. 2007;82(1):29-39. PMID: 17285783. PMID 17285783 | systematic review |
| 2015 | Testosterone | Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015;3(4):269-279. PMID: 26797061. PMC4721027. PMID 26797061 | human trial, Phase 2 |
| 2018 | Testosterone | Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364. PMID 29562364 | human study |
| 2013 | Testosterone | Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. PMID: 24024838. PMID 24024838 | human study |
| 2008 | Testosterone | Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919. PMID: 18160461. PMID 18160461 | human study |
| 2001 | Testosterone | Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-731. PMID: 11158037. PMID 11158037 | human study |
| 2025 | Testosterone | WADA. 2025 Prohibited List. Section S1 — Anabolic Agents. World Anti-Doping Agency. | regulatory / registry |
| 2023 | Testosterone | Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE; TRAVERSE Stu… PMID 37326322 | research article |
| 2018 | Testosterone | Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PMID: 29601923. PMID 29601923 | research article |
| 2016 | Testosterone | Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. PMID: 26886521. PMID 26886521 | research article |
| 2016 | Testosterone | Morgentaler A, Zitzmann M, Traish AM, Fox AW, Jones TH, Maggi M, Arver S, Aversa A, Chan JC, Dobs AS, Hackett GI, Hellstrom WJ, Lim P, Lunenfeld B, Mskhalaya G, Schulman CC, Torres LO. Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Con… PMID 27313122 | research article |
| 2016 | Testosterone | Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834-843. PMID: 28078214. PMID 28078214 | research article |
Related pair pages
More research context
Frequently asked
Have Sermorelin and Testosterone been studied together?
Researchers have published mechanistic-level co-administration discussion of Sermorelin and Testosterone. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Sermorelin and Testosterone share?
Sermorelin and Testosterone do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Sermorelin and Testosterone?
Sermorelin: Approved 1997; discontinued 2008 (commercial). Testosterone: Approved (multiple formulations). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Sermorelin and Testosterone?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Sermorelin profile and the Testosterone profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026